摘要
脑小血管疾病(CSVD)是指一类由脑小血管改变而引发的疾病,会引起多种情况,如认知功能障碍等。然而,目前对这些疾病尚无有效治疗。最近的研究表明,炎症与这种疾病相关联。环氧合酶-2(COX-2)是一种炎症介质;然而,COX-2抑制剂是否可以抑制CSVD的恶化仍然不明。本研究以脑卒中自发性高血压大鼠(SHRSP)作为CSVD的模型,以SD(SD)大鼠作为对照。用COX-2抑制剂celecoxib 或者 vehicle给药脑卒中自发性高血压大鼠。进行Morris水迷宫实验并观察脑小血管和脑组织中的血管形态和Ⅰ型胶原和纤维连接蛋白的表达。测试的结果表明,与SD大鼠相比,加厚的小血管壁使SHRSP鼠,Ⅰ型胶原和纤维连接蛋白的表达增加并使其认知功能受损。此外,celecoxib显著下调了I型胶原和纤连蛋白的表达,减少了血管壁厚度的增加并改善了认知功能障碍。我们的研究表明,该COX-2抑制剂可以作为为药理干预CSVD的有希望的候选药物。
关键词: 脑小血管病,认知障碍,胶原I,换氧化酶-2,纤连蛋白,高血压
Current Alzheimer Research
Title:A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model
Volume: 12 Issue: 7
Author(s): Jie Tang, Weizhong Xiao, Qinghua Li, Qiuqiong Deng, Xinquan Chu, Yang Chen, Danhong Pan and Jianhui Fu
Affiliation:
关键词: 脑小血管病,认知障碍,胶原I,换氧化酶-2,纤连蛋白,高血压
摘要: Cerebral small vessel disease (CSVD) is a group of diseases that originate from changes in cerebral small vessels and that cause many conditions, such as cognitive impairment. However, there is no effective therapy for these diseases. Recent studies have suggested that inflammation is associated with this disease. Cyclooxygenase-2 (cox-2) is an inflammatory mediator; however, whether a cox-2 inhibitor could protect against the CSVD progression remains unknown. In the present study, stroke-prone spontaneously hypertensive rats (SHRsp) were used as a model of CSVD, and Sprague Dawley (SD) rats served as the control. SHRsp were treated with the cox-2 inhibitor celecoxib or vehicle. The Morris water maze test was performed, and vascular morphometry and the expression of collagen I and fibronectin were examined in cerebral small vessels and cerebral tissue. The results revealed that thickened small veesel walls, increased expression of collagen I and fibronectin and impaired cognitive function in SHRsp compared with SD rats. Additionally, celecoxib significantly down-regulated the expression of collagen I and fibronectin, attenuated the increase in vascular wall thickness and ameliorates the cognitive impairment. Our study indicated that this cox-2 inhibitor may serve as a promising candidate for the pharmacological intervention of CSVD.
Export Options
About this article
Cite this article as:
Jie Tang, Weizhong Xiao, Qinghua Li, Qiuqiong Deng, Xinquan Chu, Yang Chen, Danhong Pan and Jianhui Fu , A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model, Current Alzheimer Research 2015; 12 (7) . https://dx.doi.org/10.2174/1567205012666150710104924
DOI https://dx.doi.org/10.2174/1567205012666150710104924 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin in Hypertension and Obesity
Current Hypertension Reviews Metabolic Syndrome as a Modifier of Atherosclerosis in Murine Models
Current Drug Targets Editorial [Hot Topic: Waiting for Action on the Osteoarthritis Front (Guest Editors: Virginia Byers Kraus and Thomas Aigner)]
Current Drug Targets The Role of Nano-ophthalmology in Treating Dry Eye Disease
Pharmaceutical Nanotechnology PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics
Current Drug Targets Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Cerebral Hypoperfusion During Carotid Artery Stenosis can Lead to Cognitive Deficits that may be Independent of White Matter Lesion Load
Current Neurovascular Research Long-Term Metabolic Consequences in Patients with a History of Gestational Diabetes
Current Pharmaceutical Design Passive Smoking and Coronary Heart Disease
Current Vascular Pharmacology Targeting Mitochondria for Cardiac Protection
Current Drug Targets Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics Disturbed Tryptophan Metabolism in Cardiovascular Disease
Current Medicinal Chemistry Targeting Soluble Epoxide Hydrolase for Inflammation and Pain - An Overview of Pharmacology and the Inhibitors
Inflammation & Allergy - Drug Targets (Discontinued) QT Interval Monitoring and Drugs Management During COVID-19 Pandemic
Current Reviews in Clinical and Experimental Pharmacology Tackling Cardiovascular Risk: New Evidence from Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Central Nervous System Circuitry and Peripheral Neural Sympathetic Activity Responsible for Essential Hypertension
Current Neurovascular Research The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Metabolic Syndrome, Mild Cognitive Impairment and Dementia
Current Alzheimer Research The Renin-Angiotensin System and Advanced Glycation End-Products in Diabetic Retinopathy: Impacts and Synergies.
Current Clinical Pharmacology